Empagliflozin (JARDIANCE®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease
Prof. Sarah Jarvis on Early Initiation of Empagliflozin
05/02/2025 | Author: Boehringer Ingelheim
Document ID: PC-PH-106205